Syngene Q2 FY23-24 revenue from operations up 18.5% to Rs 910 Cr
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Multi-million dollar investment augments in-vitro biology capabilities in primary and secondary screening
Lupin enters into BTA with Lupin Manufacturing Solutions
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
Animations, colors, and shapes help to improve poor situational awareness, which is responsible for 81.5% of anesthesia-related errors
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
PFA technology is only marketed in Europe, and yet, it has been dominating the electrophysiology market by storm
Tele-MANAS has counseled more than 3,50,000 people till date and currently provides counseling to 2000 people through 44 Tele Manas Cells
Ayush Minister launched month long ayurveda celebration drive of Ministry of Ayush
Two-year partnership focused on advocacy, education, and raising awareness of stroke as a global healthcare challenge
Subscribe To Our Newsletter & Stay Updated